11-19-2007, 10:41 PM
Abstract
Background Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced
gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination
in the treatment of AGC in Korean patients.
Patients and methods This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria.
Results Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6–40.3%)
and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2–4.4 months), and median overall survival
was 6.6 months (95% CI, 4.8–10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities
were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles).
Conclusion PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations
and dose regimens are, therefore, warranted.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-007-0600-yAuthors
Yeul Hong Kim, Korea University Anam Hospital Department of Internal Medicine Seoul Republic of KoreaHyun Cheol Chung, Yonsei University Severance Hospital Department of Internal Medicine Seoul Republic of KoreaWon Ki Kang, Samsung Medical Center Department of Internal Medicine Seoul Republic of KoreaSook Ryun Park, National Cancer Center Center for Gastric Cancer Goyang Gyeonggi Republic of KoreaChul Soo Kim, Inha University Hospital Department of Internal Medicine Inchon Republic of KoreaTae-Yue Kim, Seoul National University Hospital Department of Internal Medicine 28 Yeongeon-dong, Jongno-gu Seoul 110-744 Republic of KoreaSang Won Shin, Korea University Anam Hospital Department of Internal Medicine Seoul Republic of KoreaByung-Joo Park, Seoul National University Hospital Clinical Trial Center, Clinical Research Institute Seoul Republic of KoreaSoo Jin Cha, Lilly Korea Seoul Republic of KoreaYung-Jue Bang, Seoul National University Hospital Department of Internal Medicine 28 Yeongeon-dong, Jongno-gu Seoul 110-744 Republic of Korea
Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology)
Posted on Thu, 25 Oct 2007 15:00:21 +0100 at http://www.springerlink.com/content/x603l8405v7q8j51/
Author: Cancer Chemotherapy and Pharmacology
Comments: http://www.medworm.com/rss/comments.php?id=981849
Background Pemetrexed is a multitargeted antifolate enzyme inhibitor, which has activity against a variety of tumors, including advanced
gastric cancer (AGC). The aim of this study was to assess efficacy and safety of pemetrexed plus cisplatin (PemCis) combination
in the treatment of AGC in Korean patients.
Patients and methods This was a multicenter, single arm, open label study. Patients with no prior palliative chemotherapy received pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 day 1, every 3 weeks plus folic acid and vitamin B12 supplementation. Response rate was assessed according to response evaluation criteria in solid tumors (RECIST) criteria.
Results Of the 50 patients evaluable for efficacy, 13 had partial response for an overall response rate of 26% (95% CI, 14.6–40.3%)
and 15 (30%) had stable disease. Median time to progression was 2.8 months (95%CI, 2.2–4.4 months), and median overall survival
was 6.6 months (95% CI, 4.8–10.4 months). Of the 51 patients evaluable for safety, the most frequent NCI-CTC grade 3/4 toxicities
were neutropenia in 49% of patients (25% of cycles) and anorexia in 10% of patients (4% of cycles).
Conclusion PemCis has a modest activity and acceptable toxicity profile in patients with AGC. Clinical trials with different combinations
and dose regimens are, therefore, warranted.
Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-007-0600-yAuthors
Yeul Hong Kim, Korea University Anam Hospital Department of Internal Medicine Seoul Republic of KoreaHyun Cheol Chung, Yonsei University Severance Hospital Department of Internal Medicine Seoul Republic of KoreaWon Ki Kang, Samsung Medical Center Department of Internal Medicine Seoul Republic of KoreaSook Ryun Park, National Cancer Center Center for Gastric Cancer Goyang Gyeonggi Republic of KoreaChul Soo Kim, Inha University Hospital Department of Internal Medicine Inchon Republic of KoreaTae-Yue Kim, Seoul National University Hospital Department of Internal Medicine 28 Yeongeon-dong, Jongno-gu Seoul 110-744 Republic of KoreaSang Won Shin, Korea University Anam Hospital Department of Internal Medicine Seoul Republic of KoreaByung-Joo Park, Seoul National University Hospital Clinical Trial Center, Clinical Research Institute Seoul Republic of KoreaSoo Jin Cha, Lilly Korea Seoul Republic of KoreaYung-Jue Bang, Seoul National University Hospital Department of Internal Medicine 28 Yeongeon-dong, Jongno-gu Seoul 110-744 Republic of Korea
Journal Cancer Chemotherapy and PharmacologyOnline ISSN 1432-0843Print ISSN 0344-5704 (Source: Cancer Chemotherapy and Pharmacology)
Posted on Thu, 25 Oct 2007 15:00:21 +0100 at http://www.springerlink.com/content/x603l8405v7q8j51/
Author: Cancer Chemotherapy and Pharmacology
Comments: http://www.medworm.com/rss/comments.php?id=981849